FDA Approves Lilly's Insulin Glargine Biosimilar, Rezvoglar

Rezvoglar is the second "biosimilar" and the third off-brand version of the long-acting analogue insulin, originally sold as Lantus.
FDA Approvals

source https://www.medscape.com/viewarticle/965716?src=rss